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Abstract: 
 
We test the hypotheses that 1) growth hormone (GH)-releasing peptide-2 (G) synergizes with l-
arginine (A), a compound putatively achieving selective somatostatin withdrawal and 2) gender 
modulates this synergy on GH secretion. To these ends, 18 young healthy volunteers (9 men and 
9 early follicular phase women) each received separate morning intravenous infusions of saline 
(S) or A (30 g over 30 min) or G (1 μg/kg) or both, in randomly assigned order. Blood was 
sampled at 10-min intervals for later chemiluminescence assay of serum GH concentrations. 
Analysis of covariance revealed that the preinjection (basal) serum GH concentrations 
significantly determined secretagogue responsiveness and that sex (P = 0.02) and stimulus type 
(P < 0.001) determined the slope of this relationship. Nested ANOVA applied to log-transformed 
measures of GH release showed that gender determines 1) basal rates of GH secretion, 2) the 
magnitude of the GH secretory response to A, 3) the rapidity of attaining the GH maximum, 
and4) the magnitude or fold (but not absolute) elevation in GH secretion above preinjection 
basal, as driven by the combination of A and G. In contrast, the emergence of the G and A 
synergy is sex independent. We conclude that gender modulates key facets of basal and A/G-
stimulated GH secretion in young adults. 
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Article: 
 
Gender differences in basal (unstimulated) pulsatile growth hormone (GH) secretion are 
recognized in experimental animals and throughout the human lifetime (24, 28). Recent clinical 
studies have revealed other distinctions in the neuroendocrine control of GH release in men and 
women (55). For instance, Pincus et al. (40) reported that men exhibit more orderly patterns of 
GH release than women. Analogous gender differences are evident in the patterns of GH release 
in rats (28, 36). Further laboratory investigations have demonstrated differential regulation of 
hypothalamic GH-releasing hormone (GHRH) and somatostatin gene expression in male and 
female rodents (4). Distinguishable mechanisms of GH release in men and women thus are likely 
to embody sex-specific neuromodulatory inputs to the hypothalamus and/or pituitary gland. 
Gender differences also exist in GH responses to certain discrete physiological and 
pharmacological stimuli (17,27). However, there is only a limited understanding of the exact 
neuroendocrine mechanisms that drive differential GH release in men and women (53). 
 
l-Arginine (A) is a widely employed provocative test to evaluate the GH axis. Although the 
mechanism by which A releases GH in the human is not known definitively, on the basis of 
some, but not all studies, in the rat, a current proposition is that A stimulates GH release via 
withdrawal of hypothalamic somatostatin (2, 22,23). Early studies by Merimee et al. (34) 
reported that women manifest greater GH release in response to A stimulation than men and that 
this difference is due to estrogen exposure. Penelva et al. (37) reported that pyridostigmine, 
which also increases GH release at least in part via somatostatin withdrawal, slightly enhanced 
the GH secretory response to GH-related peptide (GHRP)-6. GHRP-2 (G) is a novel potent non-
GHRH peptidyl stimulus for GH release in both men and women (7). Whereas some studies have 
suggested gender differences in GH responses to GHRP, others have not (6, 9, 37). One recent 
analysis suggested that there is no gender variation in maximal GHRP-stimulated GH release but 
rather a heightened sensitivity in women to low G doses (7). 
 
In vivo in the rat and human, combined infusions of GHRH and GHRP exert synergistic rather 
than additive actions. Whereas the precise mechanistic basis for this synergism has not been 
elucidated, the two effectors clearly activate different cellular signaling pathways (1, 14). 
Moreover, each of these peptidyl agonists can partially restrain the inhibitory effects of 
somatostatin (24). 
 
The current clinical study investigates the ability of A and G to act synergistically in healthy 
young adults and tests the hypothesis that the synergy is gender dependent. 
 
METHODS 
 
Clinical protocol. Eighteen healthy subjects [9 men (means ± SE) (age = 25 ± 1.5 yr, height = 
178 ± 1.0 cm, wt = 75.1 ± 1.8 kg, total body fat = 14.5 ± 1.9%) and 9 women (age = 25 ± 1.0 yr, 
height = 169 ± 2.0 cm, wt = 66.5 ± 3.1 kg, total body fat = 22.6 ± 1.8%)] participated in the 
present study. All volunteers underwent a detailed screening medical history and complete 
physical examination and provided written informed consent as approved by the Human 
Investigation Committee at the University of Virginia. Subjects were not taking any medications 
or hormones and were moderate habitual exercisers (20–30 min of aerobic exercise, 3 or 4 
times/wk). 
 
Body density was measured by hydrostatic weighing (30). Residual lung volume was measured 
by oxygen dilution (62). Each subject was weighed in air on an Accu-weigh beam scale accurate 
to 0.1 kg and again underwater on a Chatillon autopsy scale accurate to 10 g. Percentage body fat 
was calculated using the equation of Brozek et al. (11). 
 
Subjects were admitted overnight to the General Clinical Research Center on four separate 
occasions (at rest). Admissions were scheduled at least 2 days apart and followed the study-
specific randomization schedule based on gender, which was produced by SAS (Proc Plan). 
Women were studied during the early follicular phase (days 2–8) of the menstrual cycle. 
Volunteers received a standardized constant meal, based on body weight, at 1700 the evening 
before the study. Caloric content of the meal was calculated as 0.33 × 37 kcal/kg for females and 
0.33 × 38.5 kcal/kg for males, which included an activity factor for moderate activity (19). The 
nutrient composition of the meal was fixed at 55% carbohydrate, 30% fat, and 15% protein. 
After volunteers fasted overnight, venous cannulas were placed in contralateral forearm veins at 
0500 and blood samples were withdrawn at 10-min intervals from 0600 to 1200. At 0600 on 
each admission, blood samples were obtained for later measurements of serum insulin-like 
growth factor (IGF)-1, total and free testosterone, and estradiol concentrations. At 0730, an 
intravenous infusion of either A (30 g in 300 ml) or saline (S; 300 ml) was given over 30 min. At 
0800, an intravenous bolus of either G (1 μg/kg) or S was given. Subjects rested quietly in their 
rooms during the studies. 
 
Assays. GH concentrations in all serum samples (0600–1200) were measured using a recently 
validated ultrasensitive (0.005 μg/l threshold) chemiluminescence-based assay (Nichols, San 
Juan Capistrano, CA) (13, 26, 58). The chemiluminescent assay detects predominately the 22-
kDa form of GH, with 34% cross-reactivity for 20-kDa GH (methionylated). The median intra-
assay coefficient of variation (CV) for the GH assay was 6.0%, and the interassay CV was 9.9%. 
Total testosterone, free testosterone (analog assay), and estradiol concentrations were measured 
by solid-phase RIA (Coat-a-Count, Diagnostic Products, Los Angeles, CA). The intra-assay CVs 
were 6.9, 3.8, and 3.9% for total testosterone, free testosterone and estradiol, respectively, 
whereas the interassay CVs were 10.3, 4.2, and 9.5%, respectively. Serum total IGF-1 was 
measured by RIA (Nichols). The intra-assay CV for IGF-1 was 6.7%, and the interassay CV was 
13.6%. 
 
Deconvolution analysis. A multiple-parameter deconvolution method was used to estimate 
pulsatile attributes of GH secretion from the measured serum GH concentrations (56). A pulse of 
underlying GH secretion was approximated algebraically by a Guassian distribution of secretory 
rates (54). Basal secretion (time invariant) was estimated concurrently with a subject-specific 
monoexponential half-life of endogenous GH. The stepwise procedure for deconvolution entails 
prefitting via an automated waveform-independent technique (PULSE2), in which regions 
containing significant secretion impulses of undefined waveform are identified successively 
within a time series when they significantly reduce the total fitted variance by F ratio testing 
(29). Peak locations from PULSE2 were used as estimates in the multiparameter deconvolution 
analysis, as previously described (20, 58). To avoid overdetermination of peaks (Nyquist 
concept), putative successive GH peaks separated by <20 min (2 sampling intervals apart) were 
eliminated and the data were refit. In addition, any presumptive peaks that were outside the 
sampling window (0–370 min) by more than one sampling interval (10 min) were eliminated. 
 
GH secretory pulses were considered significant if the fitted amplitude (maximal value attained 
within the computed secretory event) could be distinguished from zero with 95% statistical 
confidence. The GH secretory pulse half-duration, defined as the duration in minutes of the 
calculated secretory burst at half-maximal amplitude, GH half-life of elimination, and GH 
distribution volume were assumed to be constant throughout any one study period in any 
individual. The mass of GH secreted per pulse was estimated as the area of the calculated 
secretory pulse (μg/l distribution volume). The endogenous pulsatile GH production rate was 
defined as the product of the number of GH secretory pulses and the mean mass of GH secreted 
per pulse during 6 h. Additionally, the 90-min GH secretory burst mass, defined here as the total 
mass of GH secreted in 90 min from the end of infusions (0800–0930). This measure limits the 
effect of spurious spontaneous GH release at later times in the sampling session. 
 
Statistical procedures. Between-group comparisons were expressed in terms of fold change in 
the value of the geometric mean (GM). The GM is a location parameter, similar to the arithmetic 
mean and median, and is calculated by simply taking the antilogarithm of the mean response 
computed from the logarithmically transformed data. We compared GMs instead of arithmetic 
means, because one of the critical statistical model assumptions for ANOVA states that, to obtain 
valid statistical tests, residual variation should be approximately equal within all treatment 
groups. When the magnitude of the variance in the response increases as the mean of the 
response increases in value, the natural logarithmic transformation is generally used to stabilize 
the residual variance among two or more treatment groups (18). Therefore, data for serum sex 
steroids, IGF-1, integrated GH [area under the curve (AUC)], and calculated GH secretion 
parameters were transformed to the natural logarithm scale. Total testosterone was not 
logarithmically transformed. 
 
All ANOVA computations were carried out in SAS version 6.12 (SAS/STAT Software Changes 
and Enhancements, 1996), with the mixed model software of Proc Mixed. Parameter values were 
estimated by restricted maximum likelihood (REML), and nonexact F tests were approximated 
by using a Satterthwaite approximation (31). A Bonferroni multiplier with a prespecified 
experimental type I error rate of 0.05 was used to adjust probabilities and confidence limits to 
maintain a type I error rate of 0.05 for all comparisons of interest. All P values presented 
correspond to statistical tests that were conducted on the log-transformed response data. 
 
Total (integrated) AUC for the serum GH concentration-response curve was computed using the 
trapezoidal rule (32). These and other GH response estimates were then analyzed by a three-way 
nested ANOVA model, with gender, condition, and stimulus type considered classification 
variables. 
 
An analysis of covariance (ANCOVA) model was used to determine whether the values of basal 
preinjection GH (measured just before each stimulus) predicted subsequent GH release. As a 
component of the ANCOVA model, the basal GH level was treated as a continuous covariate. 
Classification variables for gender, condition, and stimulation were also included in the 
ANCOVA model as well as terms for two-way, three-way, and four-way interactions among the 
values of basal GH and the classification variables. Parameter values were estimated by REML 
(see above). 
 
A test of nonadditivity was used to assess the a priori hypothesis that GH release induced by 
combined G and A infusions is independent or synergistic. In this analysis, we eliminated the 
baseline intervals of GH release before and after the stimulation period, which is thus defined as 
0730–1030. A formal derivation of this statistical test for nonadditivity is included in the . Note 
that in this derivation the value of the GH response of each subject is calculated by simply 
adding his/her baseline-adjusted estimates of serum GH AUC after stimulation by A and 
stimulation by G and then subtracting this sum from the estimate of baseline-adjusted serum GH 
AUC after combined AG stimulation. This analysis thus tests the null hypothesis of no synergy 
(independence) between the GH-stimulatory effects of A and G delivered together (AG). This 
procedure was repeated for 90-min GH secretory burst mass. Nonadditivity terms were analyzed 
by a two-way nested ANOVA model, with gender and condition treated as classification 
variables. 
 
To assess power for the current investigation, values of minimum detectable fold change in the 
GM were estimated for the primary outcomes [stimulated serum GH integrated area (AUC) and 
90-min secretory burst mass] on the basis of the three-way nested ANOVA that was used in the 
analysis (45). In the computations of minimum detectable fold-change, the power of the 
statistical test was specified to be 0.80 and the type I error rate was specified to be 0.05. For 
comparisons of GH AUC and 90-min burst mass that involve two-way interactions the estimates 
of the minimum detectable fold change were 1.23 and 1.56, respectively, whereas the estimates 
were 1.47 and 2.26, respectively, for three-way interactions. 
 
 
Fig. 1. Mean serum growth hormone (GH) concentration profiles basally and in response to GH-
releasing peptide (GHRP)-2 (G) and/or l-arginine (A) infusions in men (A) and women (B). Data 
are the means ± SE. Clock time is shown. 
 
RESULTS 
 
The group serum GH concentration response patterns over time to each of the stimuli are shown 
in Fig. 1A for men and Fig. 1B for women. The maximal serum GH concentration attained was 
greatest for the AG stimulus and least for S. The rank order of stimulus strength, AG > G > A > 
S, was the same in men and women. In men, the values of the maximal serum GH concentrations 
attained after each of the stimuli were 2.4, 7.8, 36, and 73 μg/l (for S, A, G, and AG, 
respectively). These data show a 30-fold increase in the maximal serum GH concentration in 
response to AG compared with S in men. In women, the values for the S, A, G, and AG 
treatments were 6.1, 22, 43, and 93 μg/l and the increase in the maximal serum GH concentration 
for the AG compared with the S stimulus was 15-fold. Comparing the fold changes between 
women and men for each of the stimuli revealed a significant 2.8-fold [95% constant load (CL) 
(1.1,7.2)] greater GH rise in response to A in women compared with men. 
 
 
Fig. 2. Representative serum GH concentration profiles (A) and the corresponding GH secretion 
profiles (B) in an individual healthy young man and woman basally and in response to G and/or 
A infusions. Time zero corresponds to 0600 clock time in Fig. 1. 
 
In women, the time to reach the maximal serum GH concentration was greatest after the A and 
AG stimuli (50 and 60 min) compared with G (30 min). The same pattern of responses was 
observed in men, but the time to reach the maximal GH concentration was greater (delayed) for 
all three stimuli (60, 70, 40 min for A, AG, G, respectively). This consistent gender difference in 
median time to reach maximal GH concentration was highly significant (P < 0.001). 
 
Representative individual serum GH concentration vs. time curves for a man and a woman are 
shown in Fig. 2A, and the corresponding calculated GH secretion profiles assessed by 
deconvolution analysis are given in Fig. 2B (discussed below). 
 
Figure 3 presents box plots, which summarize the data for total serum integrated GH AUC 
(logarithmic scale), for men and women after each of the stimuli. Akin to maximal serum GH 
levels, the order of AUC response magnitudes was AG > G > A > S for both men and women. 
The increase in serum GH AUC for the AG compared with the S stimulus was 24-fold for men 
and 11-fold for women. The incremental change in serum GH AUC observed for each stimulus 
was influenced significantly by gender (P< 0.001). After A infusion, women had a 3.3-fold [95% 
CL(1.2,9.2)] greater median serum GH AUC than men (P < 0.001). No gender differences 
existed for the S, G, and AG stimuli. 
 
 
Fig. 3. Box plot representations of log [integrated serum GH area under curve (AUC)] basally 
and in response to G and/or A infusions in healthy young men and women. ○, Measurements 
below the 10th or above the 90th percentile. 
 
Table 1 presents data from the deconvolution analysis of GH secretory responses. The basal GH 
secretion rate was greater in women than men (P = 0.05), and this difference was consistent 
regardless of the stimulus administered. The calculated GH half-life was dependent on the 
stimulus administered (P < 0.001), but independent of gender (P = 0.9). The 90-min GH 
secretory burst mass showed a graded stimulus order, which was the same in men and women 
(AG > G > A > S). The increase in 90-min GH secretory burst mass after AG infusion compared 
with S was 242-fold for men and 40-fold for women. The incremental change in 90-min GH 
secretory burst mass for each stimuli was significantly influenced by gender (P= 0.005). In the 
control (S) session, the 90-min secretory burst mass was greater in women than men (4.8 vs. 0.88 
μg/l, P = 0.0003). Women tended to exhibit greater 90-min GH mass after A infusion (P = 
0.072). For both the G and AG stimuli, men and women had similar 90-min GH mass. 
 
Table 1. Gender comparisons of calculated GH secretion measures 
 
 
The order of response magnitude for endogenous GH production rate (AG > G > A > S) was 
identical to that of 90-min GH mass (above) for both men and women. The increase in the 
endogenous GH production rate from the S baseline to AG stimulus was 23-fold in men and 7-
fold in women. The incremental change in endogenous GH production rate from one stimulus to 
the next was influenced by gender (P < 0.001). In the S and A treatments, women had greater 
endogenous GH production rates than men (P < 0.001 and P < 0.001, respectively). Gender 
differences were not observed for the G and AG stimuli. 
 
There was a main effect of stimulus on mass of GH secreted per burst (P = 0.0001), and the 
gradation of the effect was AG > G > A > S (data not shown). The mass of GH secreted per burst 
in the combined groups increased by 3.5-fold in response to A infusion over S [95% 
CL(2.7,5.4)], by 1.7-fold for G over A stimulation [95% CL(1.1,2.5)], and by 1.8-fold for AG 
over G stimulation [95% CL(1.2,2.7)] (P < 0.001 for each). The mean GH secretory burst 
amplitude was greater in women than men for the A and S stimuli (P < 0.001 for both). Women 
had a 2.9-fold [95% CL(1.2,7.2)] greater mean GH secretory burst amplitude compared with 
men after the A stimulus and a 3.0-fold [95% CL(1.2,7.5)] greater mean GH secretory burst 
amplitude in the S (control) setting. 
 
Figure 4 shows a box plot of the results for the test of nonadditivity applied to the 90-min GH 
secretory burst mass. This analysis revealed a synergistic effect for the combined AG stimulus 
compared with the individual effects of A and G (P = 0.02). We noted that the combined AG 
stimulus compared with the summed response for (A + G) for 90-min GH secretory burst mass 
was 1.3-fold greater in women [95% CL(0.97, 1.8)] and 1.48-fold in men [95% CL(1.1,2.0)]. 
 
 
Fig. 4. Box plot representations of the test of nonadditivity of the logarithms of the 90-min GH 
secretory burst mass after combined A and G infusions (AG) vs. their algebraically summed 
individual effects (A + G). ○, Measurements below the 10th or above the 90th percentile. 
 
Figure 5 shows a box plot of the results for the test of nonadditivity for stimulated GH AUC. 
After adjustment for baseline (treatment effect at rest), the test for nonadditivity also revealed 
that the individual effects of A and G in determining GH release are not simply additive, but 
rather significantly synergistic (supra-additive) when administered in combination (joint 
stimulus, AG) (P = 0.003). The combined AG stimulus compared with summed response for (A 
+ G) was 1.6-fold greater in women [95% CL(1.2,2.0)] and 1.6-fold in men [95% CL(1.2,2.0)]. 
 
 
Fig. 5. Box plot representations of the test for nonadditivity of the logarithms of the stimulated 
serum GH AUC after combined AG infusions vs. their algebraically summed individual effects 
(A + G). ○, Measurements below the 10th or above the 90th percentile. 
 
There were no significant gender or stimulus differences in serum estradiol concentrations or 
serum IGF-1 concentrations. Men had significantly greater total and free testosterone 
concentrations (P < 0.001, for both), independent of stimulus. 
 
ANCOVA revealed that the linear relationship between log (basal serum GH AUC) and log 
(stimulated GH AUC) varied with gender (P = 0.02) and stimulus type (P < 0.001). The 
relationship between these two variables had a positive slope for the S, A, and AG stimuli, but 
not for G (results not shown). When considering all possible interactions between the log (basal 
serum GH AUC) and the indicator variables for gender and stimulus type, ANCOVA showed 
that including log (basal serum GH AUC) explains substantial residual variance otherwise 
unaccounted for by gender and stimulus (P < 0.001). However, the additional covariate [log 
(basal serum GH AUC)] failed to change the composition of the terms that were judged to be 
important in the original ANOVA model. 
 
DISCUSSION 
 
A major observation in the current study is that the effect on GH release of A and G administered 
together is not additive but rather is synergistic and that such synergism is expressed equivalently 
in men and women. Second, a gender-independent rank order of maximal GH secretory 
responses is demonstrated, i.e., AG > G > A > S. The synergistic interaction between G and A 
evoked a massive outpouring of GH over the succeeding 90 min; namely, a 242-fold (men) and a 
40-fold (women) augmentation of GH secretory burst mass over the saline control. Third, mean 
integrated and maximal serum GH concentrations, the (90 min) mass of GH secreted, GH 
secretory burst amplitude, and the GH production rate after A infusion are all higher in women 
than men. Last, a further gender difference was identified in that men had a consistent delay in 
attaining maximal serum GH concentrations compared with women. In contrast, the GH half-
life, burst duration, burst frequency, and GH secretory responses to G infusions are sex 
independent. 
 
The GH secretory response patterns to each of the distinct secretagogues were similar 
qualitatively in men and women (Fig. 1,A and B). Although the absolute value of the maximal 
serum GH concentration attained during the combined AG stimulus was greater in women than 
in men (93 vs. 73 μg/l), this difference was not statistically significant. However, given the 
gender disparity in basal (prestimulus) serum GH concentrations, we also calculated the 
fractional (fold) GH increase over basal after combined AG infusions compared with the 
unstimulated admission (S). This fold effect of AG was greater in men (30-fold) than women 
(15-fold). The augmented fractional secretory response (despite similar maximal serum GH 
concentrations) in men reflected the lower mean serum GH concentrations in the unstimulated 
state (S), as recognized in other gender comparisons (17, 52). Thus, by the way of simple 
integrated serum GH responses, men evinced a 24-fold and women an 11-fold rise above control 
(S) under joint AG drive (P< 0.001). The possible physiological role that this difference may 
play in mediating gender differences in target organs of GH action (i.e., body mass and structure) 
is unknown. 
 
The time to reach the maximal serum GH concentration was greater after the A and AG stimuli 
compared with G in both genders. For each secretagogue, men attained a maximal serum GH 
concentration ∼10 min later than women (in A, G, and AG). This temporal disparity is similar to 
that observed in a recent study using exercise as an alternative stimulus (63). Deconvolution 
analysis showed that the delay was not due to postponed GH secretion, a more prolonged GH 
half-life, or an extended GH secretory burst in men. There are several possible mechanistic 
explanations for this gender distinction. First, men's lower basal serum GH levels may have 
extended their time to reach an equivalent maximal GH peak. Second, procedural factors such as 
the introduction of intravenous fluids (S, A, or G) may have elicited unequal stress responses in 
the two sexes, given that corticotropin-releasing hormone (CRH) release (at least in the rat) 
evokes somatostatin secretion (38). In addition, the sexually dimorphic patterns of GH secretion 
are likely controlled at hypothalamic loci, as inferred from laboratory studies in rats (47, 48, 49). 
In the human, Jaffe et al. (27) also reported a gender-dependent pattern of IGF-1 feedback 
control of GH secretion, in which women exhibit reduced inhibitory responsiveness to IGF-1 
infusions, possibly reflecting a lesser effect of (daytime) somatostatin in women. Earlier, 
Carlsson et al. (12) described sexually dimorphic GH autofeedback control of GHRH and 
somatostatin actions in the adult rodent. Thus we reason that if women have diminished GH 
and/or IGF-1 (auto) negative feedback compared with men, then peak GH release may occur 
more rapidly in women than men. In this regard, application of the approximate entropy statistic, 
taken as an indirect barometer of within-axis feedback signaling, at the hypothalamic-pituitary 
level, strongly distinguished the orderliness of GH release in the female and male in both human 
and rat (40). The latter strongly suggests (but does not prove) unequal GH-IGF-1 feedback 
strength in the two sexes (60). 
 
As first described by Merimee et al. (34) over 30 years ago, we also observed that women 
attained a significantly (2.8-fold) greater maximal serum GH concentration and (3.3-fold) greater 
AUC during l-arginine infusion than men. By deconvolution analysis, we could corroborate this 
sex discrepancy and further explicate mechanistically for the first time that higher maximal 
serum GH concentrations during A infusion in women do not reflect any gender-dependent 
differences in GH half-life or GH secretory burst duration or women's higher interpulse serum 
GH concentrations, but rather is due to a specific amplification of GH secretory burst mass in the 
female. The gender difference in women's heightened GH response to A is likely estrogen 
dependent, because men also show elevated A-stimulated GH secretion after short-term estrogen 
exposure (34). However, the early follicular phase women studied here maintained serum 
estradiol concentrations that were no different from those in the normal men and still manifested 
accentuated GH release. Thus an inhibitory effect of testosterone on the GH secretory response 
to l-arginine is a possible explanation, as suggested indirectly by other earlier studies of 
spontaneous (basal) 24-h GH release in men treated with nonaromatizable androgen (59) or an 
androgen-receptor antagonist (35). This putative inhibitory effect of androgen could be mediated 
via augmented somatostatin release, as suggested in the rat (3), and/or increased responsiveness 
of the pituitary gland to somatostatin. Although clinical data relevant to the latter conjecture are 
not available to our knowledge. Recent clinical experiments indicate that estrogen does modulate 
somatostatin action in women (10). Gender differences after A are distinct and evidently do not 
extend to the putative endogenous GHRP-ligand activated pathway, because at least at the G 
dose of 1 μg/kg used here and in earlier studies, men and women exhibit similar GHRP-
stimulated GH release (present data and Refs. 6, 37). 
 
A recent clinical investigation of gender differences in GH release noted 68-fold higher morning 
ambulatory serum GH concentrations determined by immunofluorometry (IFA) in young women 
compared with young men (17). As observed earlier by immunoradiometric assay and IFA or 24-
h GH profiles (52), daily GH secretion rates are greater in young women than men. We show 
here that this gender difference is also present as assessed by ultrasensitive chemiluminescence-
based assay. Furthermore, by deconvolution analysis we could observe that the sex difference is 
accounted for solely by augmented GH secretory burst mass, but not half-life, in women. 
Although the calculated (endogenous) GH half-life rose after combined AG infusions (compared 
with the individual secretagogues), this effect was unrelated to gender. Sex invariance of GH 
half-life also was evident in experiments using recombinant human GH infusions in octreotide-
suppressed young women and men (44). The increase in estimated GH half-life observed here 
after joint AG administration thus is more likely due to the higher serum GH concentration 
attained in this context, because several investigations have reported a concentration dependence 
of metabolic clearance rate of GH in humans (25, 43, 44). 
 
In the current analysis, we calculated the mass of GH secreted over the entire 6-h study and also 
evaluated the mass of GH secreted over the 90-min poststimulus interval to obviate the effects of 
spurious spontaneous GH release at later times in the sampling session. The rank order of 
stimulus effects (AG > G > A > S) was the same for both measures. In both analyses, women 
maintained greater values in both the control (S) and A sessions compared with men, with no 
gender difference after G or combined AG infusions. 
 
Regulation of GH secretory burst amplitude explained unstimulated gender differences as well as 
the stimulatory effects of A, G, and AG infusions in this study. Thus the median GH secretory 
burst amplitude was greater in women compared with men both under control conditions and in 
response to A stimulation, but not after the G and AG stimuli. On the basis of analytic 
considerations (57), GH secretory burst amplitude thus also explicates the gradation of 
secretagogue effects (AG > G > A > S). Secretagogue drive of GH secretory burst amplitude is 
here shown to be highly specific, given the failure of any single stimulus to alter GH secretory 
burst duration, frequency, or half-life, which are the other (analytic) determinants of the serum 
GH concentration (54, 56, 57). 
 
There were no gender differences in serum IGF-1 or estradiol concentrations in this study, given 
that women were evaluated during the early follicular phase of the menstrual cycle. As expected, 
men maintained significantly greater total and free serum testosterone concentrations. Of 
interest, no sex steroid measures correlated with GH secretory responses to any of the 
secretagogue stimulus combinations used here. 
 
Available clinical studies report considerable variability in GH secretory responses to virtually 
all stimuli, e.g., exercise, GHRH challenge, etc. (42, 50, 61). This biological variability in the 
GH response has led investigators to examine the statistical power of studies with small subject 
numbers (such as the current study with 18 subjects), particularly when two- or three-way 
interactions are investigated. To this end, we performed power analysis for the primary GH 
outcome variables (stimulated GH AUC and 90-min GH burst mass) to estimate the minimal 
detectable difference required for two- and three-way interactions. For these primary outcome 
variables, the fold changes observed in the present investigation (range 3.3- to 242-fold) were 
much larger than the minimum detectable fold change values (range 1.23- to 2.26-fold), thus 
ensuring our ability to detect differences in the GH response despite the large biological 
variability. Devesa et al. (16) suggested further that the magnitude of GH release varies 
depending on the timing of GHRH infusion, i.e., whether GHRH is given during a trough or a 
peak of GH release, reflecting presumptively high or low somatostatinergic tone, respectively. 
Given this predicate, we also evaluated how the prestimulus serum GH concentration influenced 
the calculated GH secretory response in relation to gender and secretagogue type. This analysis 
revealed positive relationships between log(basal serum GH integrated AUC concentrations) and 
log(stimulated AUC serum GH concentrations) at baseline and in response to the A and AG 
stimuli, but not the G stimulus. This new observation for these secretagogues has several 
implications. First, because the linear relationship between these two variables depends on the 
secretagogue administered, it would become inappropriate to use an ANCOVA with log(basal 
GH) as a covariate for the G stimulus if the intent is to adjust treatment means (46). Second, the 
evident lack of any significant relationship between basal serum GH level and G-stimulated GH 
release warrants further mechanistic evaluation, especially because no (or a negative) correlation 
existed in both men and women. As such, the G stimulus would appear to differ mechanistically 
from A and GHRH actions (16). Anatomic evidence for interconnections between GHRH and 
somatostatin neurons in the hypothalamus (5, 33) might provide one mechanism for this 
observation. For example, an elevated basal serum GH concentration before G administration 
might impose greater GH autofeedback on endogenous GHRH (and elevated feedforward on 
somatostatin) release and thereby result in reduced (stimulated) GH secretion. This scenario 
would not prevail equally in the face of A or AG infusions, because A is believed to restrain 
somatostatin release and somatostatin is thought to mediate GH autofeedback (24). Last, our 
exploration of an ANCOVA model demonstrates that significant residual variance in selective 
secretagogue-stimulated GH secretion is indeed explicable by basal GH levels, even beyond the 
influence of gender. 
 
The mechanism underlying A-induced GH release is currently believed to include somatostatin 
withdrawal (2, 21, 22). Although this mechanism has not been confirmed directly in humans, A 
has no known direct effects on GHRH release or the GHRP effector pathway. Current evidence 
supports the view that G acts via novel, non-GHRH and non-somatostatin receptor mechanisms. 
Therefore, we predicted that the impact of combined AG stimulation on GH release would 
exceed that of either A or G alone, or their algebraically additive effects; i.e., represent a supra-
additive (or synergistic) interaction. We here support this important postulate in both men and 
women. To this end, we statistically evaluated the null hypothesis that GH release produced by 
combined AG stimulation exceeds that of the summed effects of A and G given on different 
days. Several previous clinical studies have reported synergistic (supra-additive) interactions 
between GHRP and GHRH (but A was not evaluated) on GH release in humans (6, 8, 9,39, 41), 
although another study did not (51). A synergistic interaction between GHRH and GHRP cannot 
be accounted for readily via stimulation of endogenous GHRH secretion or by inhibition of 
somatostatin release (6, 41). Alternative hypothetical mechanisms thus include inhibition of 
somatostatin actions at the pituitary level or release of another unknown hypothalamic factor (“U 
factor”). In other studies, pyridostigmine [which also presumptively acts in part via hypothalamic 
somatostatin withdrawal and in part via GHRH release (24)] augmented the GH secretory 
response to GHRP-6 (37), but did not enhance the amount of GH secreted in response to GHRH 
given with GHRP-6 (15). The authors concluded that somatotrope secretory responsiveness to 
the combined administration of GHRH and GHRP-6 is largely independent of somatostatinergic 
tone (15). However, one must also consider the possibility that maximal GH release was attained 
after combined GHRH and GHRP-6 infusions and that the addition of pyridostigmine (or any 
other stimulus) could not enhance GH secretion further. The present study indicates clearly that 
combined AG stimulation is synergistic in both men and women, i.e., greater than the summed 
effects of individual infusions of A and G (P < 0.001). To our knowledge, this is the first study 
to show a synergistic impact of A and G on GH release. In addition, we demonstrate that the 
effect of combined AG is gender independent (P = 0.28). 
 
Because the combined AG stimulus response exceeded GH release driven by the summed A plus 
G responses in both men and women, we speculate that A and G might interact in some 
excitatory manner so as to increase net GH secretion. Several hypotheses could explain the 
foregoing observation. Although considered a minor action of GHRP (7), partial attenuation of 
somatostatin action at the pituitary level by GHRP and/or release of another unknown 
hypothalamic factor by GHRP may be responsible for the synergistic action of A and G. 
Additionally, inferred bidirectional neuronal connections between GHRH, somatostatin, and/or 
endogenous GHRP-like neurons within the hypothalamus may increase net GH release during 
the combined infusion of A and G, i.e., GHRH neurons, which are known to be activated by 
GHRP in experimental animals (24), may also stimulate somatostatin withdrawal. Thereby, the 
joint AG effect could be greater than the summed effect of A and G given on separate days. 
Accordingly, further analysis of the mechanisms underlying the distinctly synergistic effects of 
A and G will likely be fruitful in future clinical and experimental investigations in both sexes. 
 
Perspectives 
 
The basis for the sexually dimorphic patterns of GH secretion in humans is a complex issue. 
Indeed, isolation of factors contributing to gender difference is made challenging by the inability 
to appraise directly in vivo each of the neuroregulatory pathways involved. The present study 
uses two selective neuroregulatory probes to explore the mechanisms underlying the sexually 
dimorphic pattern of GH secretion. Thereby, we observe both common and sex-specific features 
of GH control. First, a common effect of secretagogues on GH release is to amplify GH secretory 
burst mass in both men and women. This mechanism may be important, because data in 
experimental animals indicate that increased GH secretory burst mass and elevated basal GH 
secretion impact intermediary metabolism, hepatic gene expression, body fat deposition, and lean 
muscle mass differentially. Second, these analyses unveil several gender-specific regulatory 
features, including basal GH secretion and individual vs. synergistic secretagogue actions (see 
abstract). Finally, the prestimulus basal GH secretion rate influences the response to 
secretagogues beyond that explicated by gender alone. The predictive power of presecretagogue 
GH levels on responsiveness to A but not G thus is both gender specific and secretagogue 
dependent. The latter may be due to the unequal impact of the concurrent level of 
somatostatinergic activity on responsiveness to different specific secretagogue types. According 
to this reasoning, the response to G in either men or women could be largely independent of 
somatostatin tone. These elements of GH neuroregulation highlight the need for further 
investigations of gender differences in the multisecretagogue control of the GH-IGF-1 axis. 
 
Test of Additivity 
 
Model statement. 
 
𝑦𝑦𝑗𝑗(𝑖𝑖)𝑘𝑘𝑙𝑙 = 𝜇𝜇 + 𝜏𝜏𝑖𝑖 + 𝜌𝜌𝑗𝑗(𝑖𝑖) + 𝜆𝜆𝑘𝑘 + 𝛼𝛼𝑙𝑙 + (𝜏𝜏𝜆𝜆)𝑖𝑖𝑘𝑘 + (𝜏𝜏𝛼𝛼)𝑖𝑖𝑙𝑙 + (𝜆𝜆𝛼𝛼)𝑘𝑘𝑙𝑙 + (𝜏𝜏𝜆𝜆𝛼𝛼)𝑖𝑖𝑘𝑘𝑙𝑙 + 𝜀𝜀𝑗𝑗(𝑖𝑖)𝑘𝑘𝑙𝑙 
 
i = 1, 2 j = 1, 2,…, 9 k = 1, 2, 3 l = 1, 2  
 
where μ is the grand mean; τi, the ith gender effect, assumed to be fixed; ρj(i) is the jth subject 
effect nested within the ith gender, assumed to be random; λk is the kth treatment effect, assumed 
to be fixed; αl is the lth condition effect, assumed to be fixed; (τλ)ik is the effect of the ith gender 
by kth treatment interaction; (τα)il is the effect of the ith gender by lth condition interaction; 
(λα)kl is the effect of the kth treatment by lth condition interaction; (τλα)ikl is the effect of the ith 
gender by kth treatment by lth condition interaction; and ɛj(i)kl is the random error. 
 
Model constraints. 
 
�𝜏𝜏𝑖𝑖 = 0,�𝜆𝜆𝑘𝑘 = 0,�𝛼𝛼𝑙𝑙 = 0, 
 
��(𝜏𝜏𝜆𝜆)𝑖𝑖𝑘𝑘 = 0,��(𝜏𝜏𝛼𝛼)𝑖𝑖𝑙𝑙 = 0,  
 
��(𝜆𝜆𝛼𝛼)𝑘𝑘𝑙𝑙 = 0,���(𝜏𝜏𝜆𝜆𝛼𝛼)𝑖𝑖𝑘𝑘𝑙𝑙 = 0 
 
𝜌𝜌𝑗𝑗(𝑖𝑖)~𝑁𝑁(0,𝜎𝜎𝑠𝑠2)     𝜀𝜀𝑗𝑗(𝑖𝑖)𝑘𝑘𝑙𝑙~𝑁𝑁(0,𝜎𝜎2) 
 
Test of additivity. Let λ*1 be the baseline adjusted treatment effect of A, λ*2 be the baseline 
adjusted treatment effect of G, and λ*3 be the baseline adjusted treatment effect of combined A 
and G (AG). 
 
Note that 
 
𝑦𝑦(A+G)𝑗𝑗(𝑖𝑖)𝑙𝑙 = 2𝜇𝜇 + 2𝜏𝜏𝑖𝑖 + 2𝜌𝜌𝑗𝑗(𝑖𝑖) + (𝜆𝜆1∗ + 𝜆𝜆2∗) + 2𝛼𝛼𝑙𝑙 + 𝜏𝜏𝑖𝑖(𝜆𝜆1∗ + 𝜆𝜆2∗) + 2(𝜏𝜏𝛼𝛼)𝑖𝑖𝑙𝑙 + 𝛼𝛼𝑙𝑙(𝜆𝜆1∗ + 𝜆𝜆2∗)
+ 𝜏𝜏𝛼𝛼𝑖𝑖𝑙𝑙(𝜆𝜆1∗ + 𝜆𝜆2∗) + 𝜀𝜀(A+G)𝑗𝑗(𝑖𝑖)𝑙𝑙 
𝑦𝑦(A+G)𝑗𝑗(𝑖𝑖)𝑙𝑙 = 𝜇𝜇 + 𝜏𝜏𝑖𝑖 + 𝜌𝜌𝑗𝑗(𝑖𝑖) + 𝜆𝜆3∗ + 𝛼𝛼𝑙𝑙 + 𝜏𝜏𝑖𝑖𝜆𝜆3∗ + (𝜏𝜏𝛼𝛼)𝑖𝑖𝑙𝑙 + 𝛼𝛼𝑙𝑙(𝜆𝜆3∗) + 𝜏𝜏𝛼𝛼𝑖𝑖𝑙𝑙(𝜆𝜆3∗ ) + 𝜀𝜀(AG)𝑗𝑗(𝑖𝑖)𝑙𝑙 
𝑦𝑦(AG−A−G)𝑗𝑗(𝑖𝑖)𝑙𝑙 = 𝜇𝜇 + 𝜏𝜏𝑖𝑖 + 𝜌𝜌𝑗𝑗(𝑖𝑖) + (𝜆𝜆3∗ − 𝜆𝜆1∗ − 𝜆𝜆2∗) + 𝛼𝛼𝑙𝑙 + 𝜏𝜏𝑖𝑖(𝜆𝜆3∗ − 𝜆𝜆1∗ − 𝜆𝜆2∗) + (𝜏𝜏𝛼𝛼)𝑖𝑖𝑙𝑙
+ 𝛼𝛼𝑙𝑙(𝜆𝜆3∗ − 𝜆𝜆1∗ − 𝜆𝜆2∗) + 𝜏𝜏𝛼𝛼𝑖𝑖𝑙𝑙(𝜆𝜆3∗ − 𝜆𝜆1∗ − 𝜆𝜆2∗) + 𝜀𝜀(AG−A−G)𝑗𝑗(𝑖𝑖)𝑙𝑙
∗ . 
 
Thus for the new response y*j(i)l= y(AG−A−G)j(i)l, the model can be expressed as 
 
𝑦𝑦𝑗𝑗(𝑖𝑖)𝑙𝑙
∗ = 𝜇𝜇∗ + 𝜏𝜏𝑖𝑖 + 𝜌𝜌𝑗𝑗(𝑖𝑖) + 𝛼𝛼𝑙𝑙 + 𝜏𝜏𝛼𝛼𝑖𝑖𝑙𝑙 + 𝜀𝜀𝑗𝑗(𝑖𝑖)𝑙𝑙
∗  
 
where 
 
𝜇𝜇∗ = 𝜇𝜇 + (𝜆𝜆3∗ − 𝜆𝜆1∗ − 𝜆𝜆2∗) + 𝜏𝜏𝑖𝑖(𝜆𝜆3∗ − 𝜆𝜆1∗ − 𝜆𝜆2∗) + 𝛼𝛼𝑙𝑙(𝜆𝜆3∗ − 𝜆𝜆1∗ − 𝜆𝜆2∗) + 𝜏𝜏𝛼𝛼𝑖𝑖𝑙𝑙(𝜆𝜆3∗ − 𝜆𝜆1∗ − 𝜆𝜆2∗). 
𝜀𝜀𝑗𝑗(𝑖𝑖)𝑙𝑙
∗ = 𝜀𝜀(AG−A−G)𝑗𝑗(𝑖𝑖)𝑙𝑙
∗  
 
Hence 
 
E�𝑦𝑦𝑗𝑗(𝑖𝑖)𝑙𝑙
∗ � = E�𝜇𝜇∗ + 𝜏𝜏𝑖𝑖 + 𝜌𝜌𝑗𝑗(𝑖𝑖) + 𝛼𝛼𝑙𝑙 + (𝜏𝜏𝛼𝛼)𝑖𝑖𝑙𝑙 + 𝜀𝜀𝑗𝑗(𝑖𝑖)𝑙𝑙
∗ � = 𝜇𝜇∗ 
 
and the null hypothesis for a global test of additivity is that μ*= 0. 
 
Note 
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